In December 2025, the Food and Drug Administration (FDA) approved an oral pill form of Wegovy for weight loss, and in April 2026 approved the once-daily oral GLP-1 drug Foundayo (orforglipron) also for weight loss
Still, it can also develop following acute injury or age-related degeneration
Additionally, 40.4% of participants using CagriSema lost 25% or more of their body weight, compared to just 16.2% with semaglutide, 6.0% with cagrilintide, and less than 1% with placebo
The timeline for how much weight loss medication and how long it takes semaglutide to start working varies depending on the individual and their condition
not approved Tirzepatide (Zepbound) Approved (Zepbound, Mounjaro) Semaglutide alone (Wegovy) Approved (Wegovy, Ozempic) Cagrilintide alone Investigational Feature Head-to-head data CagriSema Did not meet non-inferiority vs tirzepatide at 84 wks (Reuters Feb 2026) Tirzepatide (Zepbound) Semaglutide alone (Wegovy) Cagrilintide alone These compounds are not interchangeable